Prime Medicine Inc (PRME)

NASDAQ
Currency in USD
1.950
0.000(0.00%)
Closed
Pre Market
1.9500.000(0.00%)
PRME Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.8501.970
52 wk Range
1.6508.270
Key Statistics
Edit
Prev. Close
1.95
Open
1.93
Day's Range
1.85-1.97
52 wk Range
1.65-8.27
Volume
1.08M
Average Vol. (3m)
1.13M
1-Year Change
-70.72%
Book Value / Share
1.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRME Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
13.100
Upside
+571.79%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Prime Medicine Inc Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Compare PRME to Peers and Sector

Metrics to compare
PRME
Peers
Sector
Relationship
P/E Ratio
−1.3x−1.0x−0.5x
PEG Ratio
−0.05−0.010.00
Price / Book
1.6x1.4x2.6x
Price / LTM Sales
83.5x6.3x3.0x
Upside (Analyst Target)
-294.1%57.1%
Fair Value Upside
Unlock34.3%10.6%Unlock

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.100
(+571.79% Upside)

Earnings

Latest Release
Feb 28, 2025
EPS / Forecast
-0.31 / -0.49
Revenue / Forecast
2.20M / --
EPS Revisions
Last 90 days

People Also Watch

27.05
YOU
-1.67%
110.64
ZBH
+0.24%
21.91
BEAM
-5.64%
156.40
KEYS
-1.31%
9.58
TXG
-1.74%

FAQ

What Is the Prime Medicine (PRME) Stock Price Today?

The Prime Medicine stock price today is 1.95

What Stock Exchange Does Prime Medicine Trade On?

Prime Medicine is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Prime Medicine?

The stock symbol for Prime Medicine is "PRME."

What Is the Prime Medicine Market Cap?

As of today, Prime Medicine market cap is 248.94M.

What is Prime Medicine Earnings Per Share?

The Prime Medicine EPS is -1.65.

What Is the Next Prime Medicine Earnings Date?

Prime Medicine will release its next earnings report on May 09, 2025.

From a Technical Analysis Perspective, Is PRME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.